- Home
- EVAX vs CMND Comparison
EVAX vs CMND Comparison
Compare EVAX & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVAX | CMND |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Denmark | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 2.6M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EVAX | CMND |
|---|---|---|
| Price | $3.09 | $0.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | 229.8K | ★ 317.2K |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $328.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.77 | $0.07 |
| 52 Week High | $12.15 | $4.66 |
Technical Indicators
Market Signals| Indicator | EVAX | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 25.38 |
| Support Level | $2.91 | $0.59 |
| Resistance Level | $3.62 | $1.27 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 35.38 | 0.60 |
Price Performance
Historical ComparisonAbout EVAX Evaxion Biotech
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.